Our results suggest that concurrent overexpression of oncogenic KRAS and mutant TP53 may be sufficient to render the imPAC2 cells tumor-like phenotype so that the imPAC cells may be exploited to model lung tumorigenesis. The gene discussed is KRAS; the disease is neoplasm.